Table 3 Most important treatment goals with current treatment
Goal, n (%) | Pooled population | Treated | Untreated | |||
|---|---|---|---|---|---|---|
Treated N = 828 | Untreated N = 405 | Expert N = 551 | Non-expert N = 277 | Expert N = 176 | Non-expert N = 229 | |
Prolong survival/reduce risk of mortality | 402 (48.6) | 174 (43.0) | 273 (49.5) | 129 (46.6) | 80 (45.5) | 94 (41.0) |
Improvement of quality of life | 314 (37.9) | 179 (44.2)* | 194 (35.2) | 120 (43.3) | 75 (42.6) | 104 (45.4) |
Overall disease stabilization | 334 (40.3) | 152 (37.5) | 234 (42.5) | 100 (36.1) | 64 (36.4) | 88 (38.4) |
Stabilization of predicted% FVC | 279 (33.7) | 56 (13.8)** | 176 (32.0) | 102 (36.8) | 23 (13.1) | 33 (14.4) |
Stabilization of quality of life | 248 (30.0) | 135 (33.3) | 164 (29.8) | 83 (30.0) | 70 (39.8) | 65 (28.4) |
Improvement of symptoms | 236 (28.5) | 142 (35.1)* | 161 (29.2) | 76 (27.4) | 57 (32.4) | 85 (37.1) |
Stabilization of symptoms | 215 (26.0) | 143 (35.3)** | 135 (24.5) | 81 (29.2) | 68 (38.6) | 75 (32.8) |
Decrease in number of exacerbations | 208 (25.1) | 94 (23.2) | 153 (27.8) | 55 (19.9) | 40 (22.7) | 53 (23.1) |
Avoid pulmonary hospitalizations | 156 (18.8) | 122 (30.1)** | 101 (18.3) | 55 (19.9) | 46 (26.1) | 76 (33.2) |
Stabilization of predicted% DLco | 92 (11.1) | 19 (4.7)** | 61 (11.1) | 31 (11.2) | 3 (1.7) | 15 (6.6) |